sibmedСибирский научный медицинский журналСибирский научный медицинский журнал2410-25122410-2520ИЦиГ СО РАН10.18699/SSMJ20220101sibmed-715Research ArticleОБЗОРЫREVIEWSНарушения метаболизма и риск заболевания COVID-19Metabolic disorders and the risk of COVID-19https://orcid.org/0000-0002-0423-5021КарасеваА. А.KarasevaA. A.

Александра Александровна Карасева

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Aleksandra A. Karaseva

630089, Novosibirsk, Boris Bogatkov str., 175/1

sas96@bk.ruhttps://orcid.org/0000-0001-7875-1566ХудяковаА. Д.KhudyakovaA. D.

Алена Дмитриевна Худякова, к.м.н.

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Alena D. Khudyakova, candidate of medical sciences

630089, Novosibirsk, Boris Bogatkov str., 175/1

alene.elene@gmail.comhttps://orcid.org/0000-0002-4936-8362РагиноЮ. И.RaginoYu. I.

Юлия Игоревна Рагино, д.м.н., проф., чл.-корр. РАН

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

 

Yuliya I. Ragino, doctor of medical sciences, professor, corresponding member RAS

630089, Novosibirsk, Boris Bogatkov str., 175/1

ragino@mail.ruНИИ терапии и профилактической медицины – филиал ФИЦ Институт цитологии и генетики СО РАНРоссияResearch Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics of Siberian Branch of Russian Academy of SciencesRussian Federation202216022022421412Copyright © Карасева А.А., Худякова А.Д., Рагино Ю.И., 20222022Карасева А.А., Худякова А.Д., Рагино Ю.И.Karaseva A.A., Khudyakova A.D., Ragino Y.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://sibmed.elpub.ru/jour/article/view/715

Целью настоящего обзора является анализ данных научной медицинской мировой литературы, посвященной изучению нарушений метаболизма и риска заболевания COVID-19. Известно, что метаболический синдром является независимым фактором риска тяжелого течения новой коронавирусной инфекции. В обзоре обобщены данные о механизмах метаболической дисфункции при COVID-19, проанализированы результаты исследований, в которых изучены вопросы ассоциаций между течением заболевания и различными метаболическими нарушениями, такими как гипергликемия и сахарный диабет, дислипидемия, ожирение, неалкогольная жировая болезнь печени, степенью их выраженности, рассмотрены потенциальные мишени терапии, предикторы развития тяжелого течения новой коронавирусной инфекции. Данные метаболические нарушения усиливают иммунный дисбаланс и делают пациентов более подверженными развитию инфекционных заболеваний, в частности к инфицированию SARS-CoV-2. Принимая во внимание вышесказанное, становится очевидным необходимость выявления и мониторинга пациентов с ранее существовавшими метаболическими заболеваниями, а также развития их во время и после COVID-19. Использованы сведения на основе баз данных PubMed, PubMed Central, Scopus, Google Scholar, Medscape, UpYoDate, eLIBRARY.RU.

In the present review the analysis of the world literature devoted to the study of metabolic disorders in the body and the risk of COVID-19 disease. It is known that metabolic syndrome is an independent risk factor for the severe course of new coronavirus infection. This review summarizes data on the mechanisms of metabolic dysfunction in a new coronavirus infection, analyzes the results of studies that investigated the issues of associations between the course of COVID-19 and various metabolic disorders, such as hyperglycemia and diabetes mellitus, dyslipidemia, obesity, non-alcoholic fatty liver disease, their severity, potential targets of therapy, predictors of the development of a severe course of new coronavirus infection are considered. These metabolic disorders increase the impairment of the immune system and make patients more susceptible to the development of infectious diseases, in particular, to infection with a new coronavirus infection. Taking into account the obtained data, it becomes obvious the need to identify and monitor patients with pre-existing metabolic diseases, as well as their development during and after COVID-19. The information on the topic from publications based on PubMed, PubMed Central, Scopus, Google Scholar, Medscape, UpYoDate, eLIBRARY.RU data were used.

COVID-19новая коронавирусная инфекцияметаболический синдроможирениегипергликемиясахарный диабетдислипидемиянеалкогольная жировая болезнь печениметаболически ассоциированная жировая болезнь печени.COVID-19new coronavirus infectionmetabolic syndromeobesityhyperglycemicdiabetes mellitusdyslipidemianon-alcoholic fatty liver diseasemetabolic dysfunction-associated fatty liver disease.Работа выполнена в рамках бюджетной темы № АААА-А19-119101490005-5 «Формирование когорт детского, подросткового, молодого населения для изучения механизмов и особенностей жизненного цикла человека в российской популяции».This work was carried out within the framework of the budget theme No. AAAA-A19-119101490005-5 “Formation of cohorts of children, adolescents, young people to study the mechanisms and characteristics of the human life cycle in the Russian population”.ReferencesWeekly epidemiological update on COVID-19 23 November 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-23-november-2021Weekly epidemiological update on COVID-19 23 November 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-23-november-2021WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. Available from: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefingon-2019-ncov-on-11-february-2020WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. Available from: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefingon-2019-ncov-on-11-february-2020Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M., Liu X.Q., Chen R.C., Tang C.L., Wang T., … China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J. 2020;5(5):2000547. doi: 10.1183/13993003.00547-2020Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M., Liu X.Q., Chen R.C., Tang C.L., Wang T., … China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J. 2020;5(5):2000547. doi: 10.1183/13993003.00547-2020Gao F., Zheng K.I., Wang X.B., Yan H.D., Sun Q.F., Pan K.H., Wang T.Y., Chen Y.P., George J., Zheng M.H. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J. Gastroenterol. Hepatol. 2021;36(1):204–207. doi: 10.1111/jgh.15112Gao F., Zheng K.I., Wang X.B., Yan H.D., Sun Q.F., Pan K.H., Wang T.Y., Chen Y.P., George J., Zheng M.H. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J. Gastroenterol. Hepatol. 2021;36(1):204–207. doi: 10.1111/jgh.15112Petrilli C.M., Jones S.A., Yang J., Rajagopalan H., O’Donnell L., Chernyak Y., Tobin K.A., Cerfolio R.J., Francois F., Horwitz L.I. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020; 369:m1966. doi: 10.1136/bmj.m1966Petrilli C.M., Jones S.A., Yang J., Rajagopalan H., O’Donnell L., Chernyak Y., Tobin K.A., Cerfolio R.J., Francois F., Horwitz L.I. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020; 369:m1966. doi: 10.1136/bmj.m1966Chai X., Hu L., Zhang Y., Han W., Lu Z., Ke A., Zhou J., Shi G., Fang N., Fan J., Cai J., Fan J., Lan F. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020.02.03.931766. doi: 10.1101/2020.02.03.931766Chai X., Hu L., Zhang Y., Han W., Lu Z., Ke A., Zhou J., Shi G., Fang N., Fan J., Cai J., Fan J., Lan F. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020.02.03.931766. doi: 10.1101/2020.02.03.931766Portincasa P., Krawczyk M., Smyk W., Lammert F., di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur. J. Clin. Invest. 2020;50(10):e13338. doi: 10.1111/eci.13338Portincasa P., Krawczyk M., Smyk W., Lammert F., di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur. J. Clin. Invest. 2020;50(10):e13338. doi: 10.1111/eci.13338Moser J.S., Galindo-Fraga A., Ortiz-Hernández A.A., Gu W., Hunsberger S., Galán-Herrera J.F., Guerrero M.L., Ruiz-Palacios G.M., Beigel J.H.; La Red ILI 002 Study Group. Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses. Influenza Other Respir. Viruses. 2019;13(1):3–9. doi: 10.1111/irv.12618Moser J.S., Galindo-Fraga A., Ortiz-Hernández A.A., Gu W., Hunsberger S., Galán-Herrera J.F., Guerrero M.L., Ruiz-Palacios G.M., Beigel J.H.; La Red ILI 002 Study Group. Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses. Influenza Other Respir. Viruses. 2019;13(1):3–9. doi: 10.1111/irv.12618Jia X., Yin C., Lu S., Chen Y., Liu Q., Bai J., Lu Y. Two things about COVID-19 might need attention. Preprints. 2020:2020020315. doi: 10.20944/preprints202002.0315.v1Jia X., Yin C., Lu S., Chen Y., Liu Q., Bai J., Lu Y. Two things about COVID-19 might need attention. Preprints. 2020:2020020315. doi: 10.20944/preprints202002.0315.v1Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W.; the Northwell COVID-19 Research Consortium, Barnaby D.P., Becker L.B., Chelico J.D., … Zanos T.P. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W.; the Northwell COVID-19 Research Consortium, Barnaby D.P., Becker L.B., Chelico J.D., … Zanos T.P. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775ICNARC Report on COVID-19 in Critical Care. 2020. Available from: www.icnarc.og.ICNARC Report on COVID-19 in Critical Care. 2020. Available from: www.icnarc.og.Lighter J., Phillips M., Hochman S., Sterling S., Johnson D., Francois F., Stachel A. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin. Infect. Dis. 2020;71(15):896–897. doi: 10.1093/cid/ciaa415Lighter J., Phillips M., Hochman S., Sterling S., Johnson D., Francois F., Stachel A. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin. Infect. Dis. 2020;71(15):896–897. doi: 10.1093/cid/ciaa415Tartof S.Y., Qian L., Hong V., Wei R., Nadjafi R.F., Fischer H., Li Z., Shaw S.F., Caparosa S.L., Nau C.L., … Murali S.B. Obesity and mortality among patients diagnosed with COVID-19: results from an Integrated Health Care Organization. Ann. Intern. Med. 2020;173(10):773–781. doi: 10.7326/M20-3742Tartof S.Y., Qian L., Hong V., Wei R., Nadjafi R.F., Fischer H., Li Z., Shaw S.F., Caparosa S.L., Nau C.L., … Murali S.B. Obesity and mortality among patients diagnosed with COVID-19: results from an Integrated Health Care Organization. Ann. Intern. Med. 2020;173(10):773–781. doi: 10.7326/M20-3742Giacomelli A., Ridolfo A.L., Milazzo L., Oreni L., Bernacchia D., Siano M., Bonazzetti C., Covizzi A., Schiuma M., Passerini M., … Galli M. 30day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol. Res. 2020;158:104931. doi: 10.1016/j.phrs.2020.104931Giacomelli A., Ridolfo A.L., Milazzo L., Oreni L., Bernacchia D., Siano M., Bonazzetti C., Covizzi A., Schiuma M., Passerini M., … Galli M. 30day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol. Res. 2020;158:104931. doi: 10.1016/j.phrs.2020.104931Yu W., Rohli K.E., Yang S., Jia P. Impact of obesity on COVID-19 patients. Diabetes Complications. 2021;35(3):107817. doi: 10.1016/j.jdiacomp.2020.107817Yu W., Rohli K.E., Yang S., Jia P. Impact of obesity on COVID-19 patients. Diabetes Complications. 2021;35(3):107817. doi: 10.1016/j.jdiacomp.2020.107817Cabandugama P.K., Gardner M.J., Sowers J.R. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med. Clin. North. Am. 2017;101(1):129–137. doi: 10.1016/j.mcna.2016.08.009Cabandugama P.K., Gardner M.J., Sowers J.R. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med. Clin. North. Am. 2017;101(1):129–137. doi: 10.1016/j.mcna.2016.08.009Шестакова М.В. Роль тканевой ренинангиотензин-альдостероновой системы в развитии метаболического синдрома, сахарного диабета и его сосудистых осложнений. Сах. диабет. 2010;13(3):14–19. doi: 10.14341/2072-0351-5481Shestakova M.V. The role of the tissue renin-angiotensin-aldosterone system in the development of metabolic syndrome, diabetes mellitus and itsvascular complications. Sakharnyy diabet = Diabetes Mellitus. [In Russian]. 2010;13(3):14–19. doi: 10.14341/20720351-5481Liu Y., Yang Y., Zhang C., Huang F., Wang F., Yuan J., Wang Z., Li J., Li J., Feng C., … Liu L. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China. Life Sci. 2020;63(3):364–374. doi: 10.1007/s11427020-1643-8Liu Y., Yang Y., Zhang C., Huang F., Wang F., Yuan J., Wang Z., Li J., Li J., Feng C., … Liu L. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China. Life Sci. 2020;63(3):364–374. doi: 10.1007/s11427020-1643-8Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet. 2005;365(16-22):1415– 1428. doi: 10.1016/S0140-6736(05)66378-7Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet. 2005;365(16-22):1415– 1428. doi: 10.1016/S0140-6736(05)66378-7Blot M., Masson D., Nguyen M., Bourredjem A.; LYMPHONIE Study Group, Binquet C., Piroth L. Are adipokines the missing link between obesity, immune response, and outcomes in severe COVID-19? Int. J. Obes. (Lond). 2021;45(9):2126–2131. doi: 10.1038/s41366-021-00868-5Blot M., Masson D., Nguyen M., Bourredjem A.; LYMPHONIE Study Group, Binquet C., Piroth L. Are adipokines the missing link between obesity, immune response, and outcomes in severe COVID-19? Int. J. Obes. (Lond). 2021;45(9):2126–2131. doi: 10.1038/s41366-021-00868-5Rebello C.J., Kirwan J.P., Greenway F.L. Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link? Int. J. Obes. (Lond). 2020;44(9):1810– 1817. doi: 10.1038/s41366-020-0640-5Rebello C.J., Kirwan J.P., Greenway F.L. Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link? Int. J. Obes. (Lond). 2020;44(9):1810– 1817. doi: 10.1038/s41366-020-0640-5Popkin B.M., Du S., Green W.D., Beck M.A., Algaith T., Herbst C.H., Alsukait R.F., Alluhidan M., Alazemi N., Shekar M. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes. Rev. 2020; 21(11):e13128. doi: 10.1111/obr.13128Popkin B.M., Du S., Green W.D., Beck M.A., Algaith T., Herbst C.H., Alsukait R.F., Alluhidan M., Alazemi N., Shekar M. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes. Rev. 2020; 21(11):e13128. doi: 10.1111/obr.13128Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W.Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003;112(12):1796–1808. doi: 10.1172/JCI19246Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W.Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003;112(12):1796–1808. doi: 10.1172/JCI19246Francisco V., Pino J., Campos-Cabaleiro V., Ruiz-Fernández C., Mera A., Gonzalez-Gay M.A., Gómez R., Gualillo O. Obesity, fat mass and immune system: role for leptin. Front. Physiol. 2018;9:640. doi: 10.3389/fphys.2018.00640Francisco V., Pino J., Campos-Cabaleiro V., Ruiz-Fernández C., Mera A., Gonzalez-Gay M.A., Gómez R., Gualillo O. Obesity, fat mass and immune system: role for leptin. Front. Physiol. 2018;9:640. doi: 10.3389/fphys.2018.00640Zhu L., She Z.G., Cheng X., Qin J.J., Zhang X.J., Cai J., Lei F., Wang H., Xie J., Wang W., … Li H. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068–1077.e3. doi: 10.1016/j.cmet.2020.04.021Zhu L., She Z.G., Cheng X., Qin J.J., Zhang X.J., Cai J., Lei F., Wang H., Xie J., Wang W., … Li H. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068–1077.e3. doi: 10.1016/j.cmet.2020.04.021Bornstein S.R., Rubino F., Khunti K., Mingrone G., Hopkins D., Birkenfeld A.L., Boehm B., Amiel S., Holt R.I., Skyler J.S., … Ludwig B. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–550. doi: 10.1016/S22138587(20)30152-2Bornstein S.R., Rubino F., Khunti K., Mingrone G., Hopkins D., Birkenfeld A.L., Boehm B., Amiel S., Holt R.I., Skyler J.S., … Ludwig B. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–550. doi: 10.1016/S22138587(20)30152-2Sheetz M.J., King G.L. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 2002;288(20):2579–2588. doi: 10.1001/jama.288.20.2579Sheetz M.J., King G.L. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 2002;288(20):2579–2588. doi: 10.1001/jama.288.20.2579Yang Y., Cai Z., Zhang J. Hyperglycemia at admission is a strong predictor of mortality and severe/ critical complications in COVID-19 patients: a metaanalysis. Biosci. Rep. 2021;41(2): BSR20203584. doi: 10.1042/BSR20203584Yang Y., Cai Z., Zhang J. Hyperglycemia at admission is a strong predictor of mortality and severe/ critical complications in COVID-19 patients: a metaanalysis. Biosci. Rep. 2021;41(2): BSR20203584. doi: 10.1042/BSR20203584Guo W., Li M., Dong Y., Zhou H., Zhang Z., Tian C., Qin R., Wang H., Shen Y., Du K., Zhao L., Fan H., Luo S., Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 2020;36(7):e3319. doi: 10.1002/dmrr.3319Guo W., Li M., Dong Y., Zhou H., Zhang Z., Tian C., Qin R., Wang H., Shen Y., Du K., Zhao L., Fan H., Luo S., Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 2020;36(7):e3319. doi: 10.1002/dmrr.3319Hojyo S., Uchida M., Tanaka K., Hasebe R., Tanaka Y., Murakami M., Hirano T. How COVID-19 induces cytokine storm with high mortality. Inflamm. Regen. 2020;40:37. doi: 10.1186/s41232-020-00146-3Hojyo S., Uchida M., Tanaka K., Hasebe R., Tanaka Y., Murakami M., Hirano T. How COVID-19 induces cytokine storm with high mortality. Inflamm. Regen. 2020;40:37. doi: 10.1186/s41232-020-00146-3Herold T., Jurinovic V., Arnreich C., Lipworth B.J., Hellmuth J.C., von Bergwelt-Baildon M., Klein M., Weinberger T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 2020;146(1):128–136.e4. doi: 10.1016/j.jaci.2020.05.008Herold T., Jurinovic V., Arnreich C., Lipworth B.J., Hellmuth J.C., von Bergwelt-Baildon M., Klein M., Weinberger T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 2020;146(1):128–136.e4. doi: 10.1016/j.jaci.2020.05.008Zhu Z., Mao Y., Chen G. Predictive value of HbA1c for in-hospital adverse prognosis in COVID-19: A systematic review and meta-analysis. Prim. Care Diabetes. 2021;15(6):910–917. doi: 10.1016/j.pcd.2021.07.013Zhu Z., Mao Y., Chen G. Predictive value of HbA1c for in-hospital adverse prognosis in COVID-19: A systematic review and meta-analysis. Prim. Care Diabetes. 2021;15(6):910–917. doi: 10.1016/j.pcd.2021.07.013Yang J.K., Lin S.S., Ji X.J., Guo L.M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193– 199. doi: 10.1007/s00592-009-0109-4Yang J.K., Lin S.S., Ji X.J., Guo L.M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193– 199. doi: 10.1007/s00592-009-0109-4Bindom S.M., Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol. Cell. Endocrinol. 2009;302(2):193–202. doi: 10.1016/j.mce.2008.09.020Bindom S.M., Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol. Cell. Endocrinol. 2009;302(2):193–202. doi: 10.1016/j.mce.2008.09.020Shrestha D.B., Budhathoki P., Raut S., Adhikari S., Ghimire P., Thapaliya S., Rabaan A.A., Karki B.J. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J. Virol. 2021;10(5):275–287. doi: 10.5501/wjv.v10.i5.275Shrestha D.B., Budhathoki P., Raut S., Adhikari S., Ghimire P., Thapaliya S., Rabaan A.A., Karki B.J. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J. Virol. 2021;10(5):275–287. doi: 10.5501/wjv.v10.i5.275Xu L., Liu J., Lu M., Yang D., Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver. Int. 2020;40(5):998–1004. doi: 10.1111/ liv.14435Xu L., Liu J., Lu M., Yang D., Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver. Int. 2020;40(5):998–1004. doi: 10.1111/ liv.14435Huang R., Zhu L., Wang J., Xue L., Liu L., Yan X., Huang S., Li Y., Yan X., Zhang B., … Wu C. Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. Hepatol. Commun. 2020;4(12):1758–1768. doi: 10.1002/hep4.1592Huang R., Zhu L., Wang J., Xue L., Liu L., Yan X., Huang S., Li Y., Yan X., Zhang B., … Wu C. Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. Hepatol. Commun. 2020;4(12):1758–1768. doi: 10.1002/hep4.1592Ji D., Qin E., Xu J., Zhang D., Cheng G., Wang Y., Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J. Hepatol. 2020;73(2):451–453. doi: 10.1016/j.jhep.2020.03.044Ji D., Qin E., Xu J., Zhang D., Cheng G., Wang Y., Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J. Hepatol. 2020;73(2):451–453. doi: 10.1016/j.jhep.2020.03.044Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y., Li Z., Zhou G., Gou J., Qu J., … Xu L. COVID-19: Abnormal liver function tests. J. Hepatol. 2020;73(3):566– 574. doi: 10.1016/j.jhep.2020.04.006Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y., Li Z., Zhou G., Gou J., Qu J., … Xu L. COVID-19: Abnormal liver function tests. J. Hepatol. 2020;73(3):566– 574. doi: 10.1016/j.jhep.2020.04.006Карасева А.А., Евдокимова Н.Е., Худякова А.Д., Стрюкова Е.В., Волкова М.В., Логвиненко И.И. Неалкогольная жировая болезнь печени и метаболические нарушения печени при новой коронавирусной инфекции. Сиб. науч. мед. ж. 2021;41(6):68–75. doi: 10.18699/SSMJ20210608Karaseva A.A., Evdokimova N.E., Khudyakova A.D., Striukova E.V., Volkova M.V., Logvinenko I.I. Non-alcoholic fatty liver disease and metabolic liver dysfunction in the new coronavirus infection COVID-19. Sibirskiy nauchnyy meditsinskiy zhurnal = Siberian Scientific Medical Journal. 2021;41(6):68–75. [In Russian]. doi: 10.18699/SSMJ20210608Zheng K.I., Gao F., Wang X.B., Sun Q.F., Pan K.H., Wang T.Y., Ma H.L., Chen Y.P., Liu W.Y., George J., Zheng M.H. Letter to the editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. doi: 10.1016/j.metabol.2020.154244Zheng K.I., Gao F., Wang X.B., Sun Q.F., Pan K.H., Wang T.Y., Ma H.L., Chen Y.P., Liu W.Y., George J., Zheng M.H. Letter to the editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. doi: 10.1016/j.metabol.2020.154244Roca-Fernández A., Dennis A., Nicholls R., McGonigle J., Kelly M., Banerjee R., Banerjee A., Sanyal A.J. Hepatic steatosis, rather than underlying obesity, increases the risk of infection and hospitalization for COVID-19. Front. Med. (Lausanne). 2021;8:636637. doi: 10.3389/fmed.2021.636637Roca-Fernández A., Dennis A., Nicholls R., McGonigle J., Kelly M., Banerjee R., Banerjee A., Sanyal A.J. Hepatic steatosis, rather than underlying obesity, increases the risk of infection and hospitalization for COVID-19. Front. Med. (Lausanne). 2021;8:636637. doi: 10.3389/fmed.2021.636637Tignanelli C.J., Bramante C.T., Dutta N., Tamariz L., Usher M.G., Ikramuddin S. Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease. Surg. Obes. Relat. Dis. 2021;17(10):1780–1786. doi: 10.1016/j.soard.2021.05.029Tignanelli C.J., Bramante C.T., Dutta N., Tamariz L., Usher M.G., Ikramuddin S. Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease. Surg. Obes. Relat. Dis. 2021;17(10):1780–1786. doi: 10.1016/j.soard.2021.05.029Zuin M., Rigatelli G., Bilato C., Cervellati C., Zuliani G., Roncon L. Prognostic role of metabolic syndrome in COVID-19 patients: a systematic review meta-analysis. Viruses. 2021;13(10):1938. doi: 10.3390/v13101938Zuin M., Rigatelli G., Bilato C., Cervellati C., Zuliani G., Roncon L. Prognostic role of metabolic syndrome in COVID-19 patients: a systematic review meta-analysis. Viruses. 2021;13(10):1938. doi: 10.3390/v13101938Lorizate M., Kräusslich H.G. Role of lipids in virus replication. Cold Spring Harb. Perspect. Biol. 2011;3(10):a004820. doi: 10.1101/cshperspect. a004820Lorizate M., Kräusslich H.G. Role of lipids in virus replication. Cold Spring Harb. Perspect. Biol. 2011;3(10):a004820. doi: 10.1101/cshperspect. a004820Cirstea M., Walley K.R., Russell J.A., Brunham L.R., Genga K.R., Boyd J.H. Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. J. Crit. Care. 2017;38:289–294. doi: 10.1016/j.jcrc.2016.11.041Cirstea M., Walley K.R., Russell J.A., Brunham L.R., Genga K.R., Boyd J.H. Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. J. Crit. Care. 2017;38:289–294. doi: 10.1016/j.jcrc.2016.11.041Hardt M., Schwudke D., Neuman B.W., Pleschka S., Ziebuhr J. Inhibition of cytosolic phospholipase A2α impairs an early step of coronavirus replication in cell culture. J. Virol. 2018;92(4):e01463–17. doi: 10.1128/JVI.01463-17Hardt M., Schwudke D., Neuman B.W., Pleschka S., Ziebuhr J. Inhibition of cytosolic phospholipase A2α impairs an early step of coronavirus replication in cell culture. J. Virol. 2018;92(4):e01463–17. doi: 10.1128/JVI.01463-17Barberis E., Timo S., Amede E., Vanella V.V., Puricelli C., Cappellano G., Raineri D., Cittone M.G., Rizzi E., Pedrinelli A.R., … Manfredi M. Large-scale plasma analysis revealed new mechanisms and molecules associated with the host response to SARSCoV-2. Int. J. Mol. Sci. 2020;21(22):8623. doi: 10.3390/ijms21228623Barberis E., Timo S., Amede E., Vanella V.V., Puricelli C., Cappellano G., Raineri D., Cittone M.G., Rizzi E., Pedrinelli A.R., … Manfredi M. Large-scale plasma analysis revealed new mechanisms and molecules associated with the host response to SARSCoV-2. Int. J. Mol. Sci. 2020;21(22):8623. doi: 10.3390/ijms21228623Bock J.O., Ortea I. Re-analysis of SARS-CoV2-infected host cell proteomics time-course data by impact pathway analysis and network analysis: a potential link with inflammatory response. Aging (Albany NY). 2020;12(12):11277–11286. doi: 10.18632/aging.103524Bock J.O., Ortea I. Re-analysis of SARS-CoV2-infected host cell proteomics time-course data by impact pathway analysis and network analysis: a potential link with inflammatory response. Aging (Albany NY). 2020;12(12):11277–11286. doi: 10.18632/aging.103524Abu-Farha M., Thanaraj T.A., Qaddoumi M.G., Hashem A., Abubaker J., Al-Mulla F. The role of lipid metabolism in COVID-19 virus infection and as a drug target. Int. J. Mol. Sci. 2020;21(10):3544. doi: 10.3390/ijms21103544Abu-Farha M., Thanaraj T.A., Qaddoumi M.G., Hashem A., Abubaker J., Al-Mulla F. The role of lipid metabolism in COVID-19 virus infection and as a drug target. Int. J. Mol. Sci. 2020;21(10):3544. doi: 10.3390/ijms21103544Mahat R.K., Rathore V., Singh N., Singh N., Singh S.K., Shah R.K., Garg C. Lipid profile as an indicator of COVID-19 severity: A systematic review and meta-analysis. Clin. Nutr. ESPEN. 2021;45:91–101. doi: 10.1016/j.clnesp.2021.07.023Mahat R.K., Rathore V., Singh N., Singh N., Singh S.K., Shah R.K., Garg C. Lipid profile as an indicator of COVID-19 severity: A systematic review and meta-analysis. Clin. Nutr. ESPEN. 2021;45:91–101. doi: 10.1016/j.clnesp.2021.07.023Hu X., Chen D., Wu L., He G., Ye W. Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection. Clin. Chim. Acta. 2020;510:105–110. doi: 10.1016/j.cca.2020.07.015Hu X., Chen D., Wu L., He G., Ye W. Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection. Clin. Chim. Acta. 2020;510:105–110. doi: 10.1016/j.cca.2020.07.015Zuin M., Rigatelli G., Bilato C., Cervellati C., Zuliani G., Roncon L. Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis. QJM. 2021;114(6):390–397. doi: 10.1093/qjmed/hcab071Zuin M., Rigatelli G., Bilato C., Cervellati C., Zuliani G., Roncon L. Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis. QJM. 2021;114(6):390–397. doi: 10.1093/qjmed/hcab071Kim J.A., Montagnani M., Chandrasekran S., Quon M.J. Role of lipotoxicity in endothelial dysfunction. Heart Fail. Clin. 2012;8(4):589–607. doi: 10.1016/j. hfc.2012.06.012Kim J.A., Montagnani M., Chandrasekran S., Quon M.J. Role of lipotoxicity in endothelial dysfunction. Heart Fail. Clin. 2012;8(4):589–607. doi: 10.1016/j. hfc.2012.06.012Froldi G., Dorigo P. Endothelial dysfunction in Coronavirus disease 2019 (COVID-19): Gender and age influences. Med. Hypotheses. 2020;144:110015. doi: 10.1016/j.mehy.2020.110015Froldi G., Dorigo P. Endothelial dysfunction in Coronavirus disease 2019 (COVID-19): Gender and age influences. Med. Hypotheses. 2020;144:110015. doi: 10.1016/j.mehy.2020.110015Kaji H. High-density lipoproteins and the immune system. J. Lipids. 2013;2013:684903. doi: 10.1155/2013/684903Kaji H. High-density lipoproteins and the immune system. J. Lipids. 2013;2013:684903. doi: 10.1155/2013/684903McKechnie J.L., Blish C.A. The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell Host Microbe. 2020;27(6):863– 869. doi: 10.1016/j.chom.2020.05.009McKechnie J.L., Blish C.A. The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell Host Microbe. 2020;27(6):863– 869. doi: 10.1016/j.chom.2020.05.009Wang G., Zhang Q., Zhao X., Dong H., Wu C., Wu F., Yu B., Lv J., Zhang S., Wu G., Wu S., Wang X., Wu Y., Zhong Y. Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. Lipids Health Dis. 2020;19(1):204. doi: 10.1186/s12944-020-01382-9Wang G., Zhang Q., Zhao X., Dong H., Wu C., Wu F., Yu B., Lv J., Zhang S., Wu G., Wu S., Wang X., Wu Y., Zhong Y. Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. Lipids Health Dis. 2020;19(1):204. doi: 10.1186/s12944-020-01382-9Wei X., Zeng W., Su J., Wan H., Yu X., Cao X., Tan W., Wang H. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol. 2020;14(3):297–304. doi: 10.1016/j.jacl.2020.04.008Wei X., Zeng W., Su J., Wan H., Yu X., Cao X., Tan W., Wang H. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol. 2020;14(3):297–304. doi: 10.1016/j.jacl.2020.04.008Fan J., Wang H., Ye G., Cao X., Xu X., Tan W., Zhang Y. Letter to the editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism. 2020;107:154243. doi: 10.1016/j.metabol.2020.154243Fan J., Wang H., Ye G., Cao X., Xu X., Tan W., Zhang Y. Letter to the editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism. 2020;107:154243. doi: 10.1016/j.metabol.2020.154243Aparisi Á., Iglesias-Echeverría C., Ybarra-Falcón C., Cusácovich I., Uribarri A., García-Gómez M., Ladrón R., Fuertes R., Candela J., Tobar J., … Andaluz-Ojeda D. Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19. Nutr. Metab. Cardiovasc. Dis. 2021;31(9):2619–2627. doi: 10.1016/j.numecd.2021.06.016Aparisi Á., Iglesias-Echeverría C., Ybarra-Falcón C., Cusácovich I., Uribarri A., García-Gómez M., Ladrón R., Fuertes R., Candela J., Tobar J., … Andaluz-Ojeda D. Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19. Nutr. Metab. Cardiovasc. Dis. 2021;31(9):2619–2627. doi: 10.1016/j.numecd.2021.06.016Dobiasova M., Frohlich J., Sedova M., Cheung M.C., Brown B.G. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J. Lipid Res. 2011;52(3):566–571. doi: 10.1194/jlr.P011668Dobiasova M., Frohlich J., Sedova M., Cheung M.C., Brown B.G. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J. Lipid Res. 2011;52(3):566–571. doi: 10.1194/jlr.P011668Onat A., Can G., Kaya H., Hergenç G. «Atherogenic index of plasma» (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J. Clin. Lipidol. 2010;4(2):89–98. doi: 10.1016/j.jacl.2010.02.005Onat A., Can G., Kaya H., Hergenç G. «Atherogenic index of plasma» (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J. Clin. Lipidol. 2010;4(2):89–98. doi: 10.1016/j.jacl.2010.02.005Yildiz G., Duman A., Aydin H., Yilmaz A., Hür E., Mağden K., Cetin G., Candan F. Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis. Hemodial. Int. 2013;7(3):397–405. doi: 10.1111/hdi.12041Yildiz G., Duman A., Aydin H., Yilmaz A., Hür E., Mağden K., Cetin G., Candan F. Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis. Hemodial. Int. 2013;7(3):397–405. doi: 10.1111/hdi.12041Niroumand S., Khajedaluee M., Khadem-Rezaiyan M., Abrishami M., Juya M., Khodaee G., Dadgar-moghaddam M. Atherogenic index of plasma (AIP): A marker of cardiovascular disease. Med. J. Islam. Repub. Iran. 2015;29:240.Niroumand S., Khajedaluee M., Khadem-Rezaiyan M., Abrishami M., Juya M., Khodaee G., Dadgar-moghaddam M. Atherogenic index of plasma (AIP): A marker of cardiovascular disease. Med. J. Islam. Repub. Iran. 2015;29:240.Turgay Yıldırım Ö., Kaya Ş. The atherogenic index of plasma as a predictor of mortality in patients with COVID-19. Heart Lung. 2021;50(2):329–333. doi: 10.1016/j.hrtlng.2021.01.016Turgay Yıldırım Ö., Kaya Ş. The atherogenic index of plasma as a predictor of mortality in patients with COVID-19. Heart Lung. 2021;50(2):329–333. doi: 10.1016/j.hrtlng.2021.01.016

The authors declare that there are no conflicts of interest present.